文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

从临床试验到临床实践:澳大利亚与新西兰前列腺SABR实践模式调查

From Clinical Trials to Clinical Practice-Patterns of Practice Survey on Prostate SABR in Australia and New Zealand.
PubMed 文献 · Adv Radiat Oncol · 2026-07-17

该调查由澳大利亚与新西兰放射肿瘤学院在制定前列腺SABR指南过程中委托开展,面向澳新泌尿生殖系放射肿瘤医生进行横断面调查,共53人回应(回应率28%)。41名当前提供前列腺SABR的医生中,对有利中危、不利中危、有利高危、极高危和淋巴结阳性患者提供SABR的比例分别为95%、90%、35%、5%和0%。

要点

  • 有利中危和不利中危前列腺癌患者中,分别有95%和90%的医生将SABR作为标准治疗选择。
  • 最常用剂量分割为5次给予PTV 36.25 Gy、CTV 40 Gy,多数医生每周治疗2至3次。
  • 不提供SABR的主要障碍为缺乏专业经验(42%),实践在靶区勾画和PTV外扩上存在差异。

核心结论

  • 澳新地区前列腺SABR实践存在一定差异,调查反映了当代实践模式并揭示了推广障碍。

研究设计与样本

  • 横断面实践模式调查,面向澳大利亚与新西兰泌尿生殖系放射肿瘤医生,共53人回应(回应率28%)。

主要发现

  • 41名当前提供前列腺SABR的医生中,对有利中危、不利中危、有利高危、极高危和淋巴结阳性患者提供SABR的比例分别为95%、90%、35%、5%和0%。
  • 86%的医生常规使用基准标记物,所有医生常规申请计划MRI用于勾画。
  • 临床靶区勾画从仅前列腺(26%)到前列腺加精囊近端1 cm(81%)不等,PTV外扩范围为3至5 mm。
  • 最常见的外扩为各向异性5 mm、后方3 mm(56%),45%的医生对前列腺内病灶给予局部加量。

关键数值与推荐

  • 最常用剂量分割为5次给予PTV 36.25 Gy和CTV 40 Gy,50%的医生每周治疗2次、76%每周治疗3次。
  • 治疗平台包括标准CT-LINAC(88%)、CyberKnife(10%)和磁共振-LINAC(5%)。

临床怎么用

  • 调查结果可为澳新地区前列腺SABR指南制定提供 contemporaneous 实践基线,并提示需针对缺乏专业经验这一障碍开展培训与推广。

局限性

  • 调查回应率为28%,结果可能不能完全代表澳新地区全部放射肿瘤医生的实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate stereotactic ablative body radiotherapy (SABR) is now a standard-of-care radiation therapy option for prostate cancer based on high-level clinical trial evidence. As part of the Australia and New Zealand (ANZ) prostate SABR guideline development process, the Royal Australian and New Zealand College of Radiologists has commissioned a pattern-of-practice survey on contemporaneous prostate SABR practice. METHODS AND MATERIALS: We conducted a cross-sectional survey among ANZ genitourinary radiation oncologists (ROs), focusing on patient selection, contouring, treatment planning, and delivery of prostate SABR. RESULTS: A total of 53 ROs across ANZ responded to the survey (response rate: 28%). Of the 41 ROs currently offering prostate SABR, 95%, 90%, 35%, 5%, and 0% offer prostate SABR as standard-of-care options to individuals with favorable intermediate risk, unfavorable intermediate risk, favorable high risk (NINJA/ TROG18.01 trial eligible), very high risk, and node-positive prostate cancer, respectively. Most ROs (86%) routinely use fiducial markers. All ROs routinely request planning magnetic resonance imaging for contouring. Clinical target volume contouring ranged from prostate alone (26%) to prostate plus proximal 1 cm of the seminal vesicles (81%). Planning target volume margins ranged from 3 to 5 mm. An anisotropic 5 mm margin with 3 mm posteriorly was most common (56%). Nineteen (45%) ROs provide a focal boost to the intraprostatic lesion. The most common dose fractionation was 36.25 Gy to the planning target volume and 40 Gy to the clinical target volume over 5 fractions, delivered as 2 (50%) to 3 fractions (76%) per week. The majority of ROs offer prostate SABR on standard computed tomography-linear accelerator (LINAC) (88%), with several ROs also treating patients with CyberKnife (10%) and magnetic resonance-LINAC (5%). Of the ROs who use standard computed tomography-LINAC, 84% use intrafraction motion monitoring. Twelve (23%) ROs do not offer prostate SABR. The main barrier cited was a lack of expertise (42%). CONCLUSIONS: This ANZ-wide prostate SABR pattern-of-practice survey demonstrated some variations in practice, providing contemporary insight into how prostate SABR is delivered across ANZ and highlighting barriers to wider adoption.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kang T, Armstrong S, Chander S, et al. From Clinical Trials to Clinical Practice-Patterns of Practice Survey on Prostate SABR in Australia and New Zealand. Adv Radiat Oncol. 2026. PMID: 42656846. doi:10.1016/j.adro.2026.102144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。